Magazine Article | April 1, 2021

Companies To Watch: Carisma Therapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Dialing M for Macrophage in CAR-M

SNAPSHOT

Carisma Therapeutics is a private company developing CAR-M (chimeric antigen receptor macrophage) as an alternative to CAR-T (CAR-T cell) and potential treatment for solid tumors rather than just liquid cancers. Both technologies are forms of adoptive cell transfer — typically extracting the patient’s own immune cells, reprogramming them to kill cancer cells in the patient, and replacing them in the same patient to fight the cancer. CAR-M uses macrophages, which enlist the innate immune system and may overcome some of the protective barriers in the tumor microenvironment. Carisma has three agents in its pipeline, one in a Phase 1 trial, two in preclinical research.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: